Lastly, a cytotoxicity assay was conducted to assess the antiproliferative properties of the constructed VLPs in breast cancer cells that overexpress HER2 and triple negative breast cancer cells that lack such an overexpression. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.